Literature DB >> 638469

Haemodialysis during cyclophosphamide treatment.

R A Milsted, M Jarman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 638469      PMCID: PMC1603547          DOI: 10.1136/bmj.1.6116.820-a

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  4 in total

1.  [ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].

Authors:  N BROCK; H J HOHORST
Journal:  Arzneimittelforschung       Date:  1963-12

2.  The quantitation of cyclophosphamide in human blood and urine by mass spectrometry-stable isotope dilution.

Authors:  M Jarman; E D Gilby; A B Foster; P K Bondy
Journal:  Clin Chim Acta       Date:  1975-01-06       Impact factor: 3.786

3.  The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

Authors:  H T Mouridsen; O Faber; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-08

4.  Clinical pharmacology of cyclophosphamide.

Authors:  C M Bagley; F W Bostick; V T DeVita
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

  4 in total
  3 in total

Review 1.  Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors:  Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

3.  Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.

Authors:  Hajime Yasuda; Mutsuko Yasuda; Norio Komatsu
Journal:  Cancer Sci       Date:  2021-06-11       Impact factor: 6.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.